Sign in Subscribe
Genetic research

Comparison of Enzymatic and Bisulfite Conversion of Biomarkers for Cancer Management

Strategic Insights

— 1 min read

A recent study conducted by Oslo University Hospital has compared the efficacy of enzymatic and bisulfite conversion methods for detecting DNA methylation biomarkers in circulating cell-free DNA (cfDNA). The research, aimed at optimizing and standardizing a critical pre-treatment method for DNA methylation analyses, has revealed that bisulfite conversion emerges as the best pre-treatment method due to its higher DNA recovery rate and more accurate results.

Key Takeaways:

  • Enzymatic conversion of DNA, a promising alternative to bisulfite conversion, resulted in longer DNA fragments but lower DNA recovery rates, ranging from 34-47%.
  • Bisulfite conversion, the gold-standard pre-treatment method, achieved DNA recovery rates of 61-81% and higher cytosine conversion efficiency (99-100%).
  • A comparison of five magnetic bead brands and different magnetic bead-to-sample ratios revealed no significant improvements in DNA recovery for enzymatic conversion.
  • DNA methylation of the biomarker BCAT1 was detected at similar rates in parallel tumor cfDNA samples pre-treated with either enzymatic or bisulfite conversion.
  • Enzymatic conversion resulted in lower numbers of positive droplets for both target and control ddPCR assays, aligning with lower DNA recovery rates.

Statistics:

  • 99-100% cytosine conversion efficiency achieved by both enzymatic and bisulfite conversion.
  • DNA recovery rates: enzymatic conversion (34-47%), bisulfite conversion (61-81%).
  • Number of positive droplets for both target and control ddPCR assays: enzymatic conversion (lower numbers) vs. bisulfite conversion (higher numbers).

Sources:

  • "Comparison of enzymatic and bisulfite conversion of circulating cell-free tumor DNA for DNA methylation analyses." Clinical Epigenetics, 2025,17(1):1-13. (Clinical Epigenetics - http://www.clinicalepigeneticsjournal.com/).
  • Kreftforeningen; The Norwegian Esophageal Cancer Consortium; Helse SoR-ost Rhf; University of Oslo (research funders).
  • NewsRx. Research from Oslo University Hospital Reveals New Findings on Biomarkers (Comparison of enzymatic and bisulfite conversion of circulating cell-free tumor DNA for DNA methylation analyses). Health & Medicine Week. June 27, 2025; p 3523.

Read more